OpRegen® for Dry-AMD in Trials

BioTime, Inc. is expanding its ongoing Phase I/IIa clinical trial for OpRegen® for treatment of dry AMD. by naming the first two sites that will treat patients in the U.S.

Adi Mohanty, Co-Chief Executive Officer of BioTime, said, “We are honored to be working with two of the leading U.S. clinicians in ophthalmology, Dr. David S. Boyer and Dr. H. Richard McDonald. The sites are currently going through the set-up process, and we anticipate enrolling and treating U.S.-based patients by the end of the second quarter.”

David S. Boyer, M.D., is an ophthalmologist and senior partner with Retina-Vitreous Associates Medical Group in Los Angeles, and H. Richard McDonald, M.D., is an ophthalmologist and senior partner at West Coast Retina Medical Group in San Francisco.

OpRegen® is an investigational therapy in which retinal pigment epithelial (RPE) cells are introduced into the subretinal space where they are intended to replace missing RPE cells. As reported at the International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) in Rome on December 2, 2016 and at the Angiogenesis meeting in Miami on February 11, 2017, OpRegen® caused no serious adverse events, and retinal imaging suggests the presence and survival of transplanted cells in the subretinal space for up to one year.

For continually-updated information about more treatments under study for dry AMD, see A Guide to Research in Dry AMD on this site.

Source: BioTime press release